Health
LCMC3 trial: Neoadjuvant atezolizumab prior to lung cancer surgery meets primary endpoint – News-Medical.Net
(Primary analysis of the Lung Cancer Mutation Consortium (LCMC) 3 study revealed that neoadjuvant atezolizumab prior to lung cancer surgery was well tolerated by…
(Primary analysis of the Lung Cancer Mutation Consortium (LCMC) 3 study revealed that neoadjuvant atezolizumab prior to lung cancer surgery was well tolerated by patients and met its primary endpoint of 20% major pathologic response rate, according to research presented today at the International Association for the Study of Lung Cancer’s World Conference on Lung Cancer.
Dr. Jay M. Lee, chief, Division of Thoracic Surgery at Ronald Reagan UCLA Medical Center in Los Angeles, today reported on results…
-
General15 hours agoCampers evacuated, residents on alert as Moreton Island bushfire intensifies
-
Noosa News22 hours agoPerth Royal Show vendors upset by price hikes, say crowds are down in 2025
-
Business23 hours agoBell Potter names the best ASX shares to buy in October
-
General21 hours agoAustralia welcomes Gaza peace progress, hostage release